IR208 Uses, Dosage, Side Effects and more
IR208 is a synthetic T-Cell receptor peptidevaccine developed by Immune Response Corporation.It contains three peptides (BV5S2, BV6S5and BV13S1) expressed by T-Cells in over 90% of MSpatients. IR208 is currently undergoing Phase IIstudies in a 200-patient trial.
| Trade Name | IR208 |
| Generic | IR208 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in multiple sclerosis.
